Sandra Black, MD, FRCP(C) is an internationally renowned cognitive and stroke neurologist who holds the inaugural Brill Chair in Neurology, Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre. A leading clinical trialist in dementia, she is the current Executive Director of the Toronto Dementia Research Alliance, a multi institutional collaborative network of memory programs at the University of Toronto involving Baycrest, Centre for Addiction and Mental Health, St. Michael’s Hospital, Sunnybrook HSC and Toronto Western Hospital, UHN. She is also the Sunnybrook Site Director of the Heart & Stroke Foundation Canadian Partnership for Stroke Recovery and the Hurvitz Brain Sciences Research Program Director at Sunnybrook Research Institute. In 2011 she was named to the Order of Ontario, cited as an assiduous physician leader and influential architect of the Ontario Stroke System. She has authored/co-authored over 450 papers in a 25-year research career that has bridged dementia and stroke, using neuroimaging to study brain behavior relationships, with a recent focus on interactions of Alzheimer’s and silent stroke disease. She has earned numerous mentorship and research awards, and elected to the Royal Society of Canada in 2012. In 2015 she received the U of T Faculty of Medicine Dean’s Alumni Lifetime Achievement Award and was appointed an Officer to the Order of Canada for her contributions to Alzheimer’s disease, stroke and vascular dementia.
dementia, apraxia, stroke recovery, neurorehabilitation, vascular cognitive impairment, cognitive neuroscience, neurodegenerative disorders, Lewy body dementia, frontotemporal dementia, neuroimaging biomarkers, cerebral small vessel disease, brain imaging analysis, Alzheimer disease, primary progressive aphasia (PPA)
Dr. Black's research foci include the following:
- Mild cognitive impairment and Alzheimer’s disease
- Vascular cognitive impairment and cerebral small vessel disease
- Parkinson’s disease, Lewy body spectrum disorder and frontotemporal dementia (behavioural variant, primary progressive aphasia)
- Apraxia and aphasia
- Stroke recovery
- Clinical trials in dementia and its prevention
- Neuroimaging biomarkers and brain-behaviour relationships
Harmonizing brain magnetic resonance imaging methods for vascular contributions to neurodegeneration.
Alzheimers Dement (Amst). 2019 Dec;11:191-204
Brain. 2019 Mar 07;:
J Nucl Med. 2019 Feb 07;:
BOLD-based cerebrovascular reactivity vascular transfer function isolates amplitude and timing responses to better characterize cerebral small vessel disease.
NMR Biomed. 2019 Jan 29;:e4064
Alzheimers Dement. 2019 Jan;15(1):158-167
J Magn Reson Imaging. 2019 Feb;49(2):456-465
Alzheimers Res Ther. 2019 Jan 05;11(1):1
Correction to: The Toronto cognitive assessment (TorCA): normative data and validation to detect amnestic mild cognitive impairment.
Alzheimers Res Ther. 2018 Dec 07;10(1):120
Soluble Epoxide Hydrolase-Derived Linoleic Acid Oxylipins in Serum Are Associated with Periventricular White Matter Hyperintensities and Vascular Cognitive Impairment.
Transl Stroke Res. 2018 Nov 15;:
The Impact of Covert Lacunar Infarcts and White Matter Hyperintensities on Cognitive and Motor Outcomes After Stroke.
J Stroke Cerebrovasc Dis. 2018 Nov 05;:
Brill Chair in Neurology, University of Toronto, Sunnybrook Health Sciences Centre